U.S. markets closed

Aligos Therapeutics, Inc. (ALGS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.4300+0.0300 (+2.14%)
At close: 04:00PM EDT
1.4300 0.00 (0.00%)
After hours: 04:02PM EDT

Aligos Therapeutics, Inc.

One Corporate Drive
2nd Floor
South San Francisco, CA 94080
United States
800 466 6059

Full Time Employees89

Key Executives

NameTitlePayExercisedYear Born
Dr. Lawrence M. Blatt MBA, Ph.D.CEO & Chairman872.58kN/A1962
Dr. Leonid Beigelman Ph.D.Pres & Director702.25kN/A1959
Dr. Julian A. Symons DPHILExec. VP & Chief Scientific Officer618.82kN/A1961
Ms. Lesley Ann Calhoun CPAExec. VP & CFON/AN/A1966
Ms. Lucinda Y. Quan J.D.Exec. VP, Chief Bus. Officer & Gen. CounselN/AN/A1972
Mr. John FryExec. VP of Clinical Devel.N/AN/A1963
Dr. Matthew W. McClure M.D.Exec. VP & Chief Medical OfficerN/AN/A1972
Dr. Sushmita M. Chanda DABT, Ph.D.Exec. VP of Translational Safety SciencesN/AN/A1966
Dr. David B. Smith Ph.D.Exec. VP & Head of Chemical OperationsN/AN/AN/A
Dr. Tse-I Lin Ph.D.VP of Early Compound Devel. & Belgian Site HeadN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Corporate Governance

Aligos Therapeutics, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.